RXO, Inc. (NYSE: RXO) has garnered renewed investor attention following a recent upgrade to a Buy rating from J. Bruce Chan of Stifel on May 15, 2026. This rating shift highlights the firm’s optimism regarding the stock, given its current trading price of $17.51 and an ambitious price target set at $22. For investors, this is a notable signal that could encourage consideration of RXO as an attractive investment opportunity.
Recent Price Action
In the last trading sessions, RXO experienced notable volatility, ultimately closing at $17.51, an increase of $1.49 or approximately 8.51% on the day. This uptick is encouraging in light of its 52-week performance, where the stock has fluctuated between a low of $49.45 and a high of -$24.73. The trading volume stood at 1,933,944, slightly below the average volume of 2,039,447, indicating a fair level of investor interest. With a market capitalization of around $3.13 billion and a beta of 1.853, RXO reflects a relatively high level of volatility compared to the broader market, suggesting that investors might anticipate further price movements in either direction.
Historical Performance
Over the last month, RXO has shown a positive return of 5.4%, providing some relief amid broader market fluctuations. However, this performance contrasts starkly with the 90-day results, where the stock declined by 15.08%. Over a year, RXO has faced significant challenges, reporting a staggering 42.75% loss. The stock’s volatility metrics indicate a 4.26% weekly and 4.67% monthly volatility rate, which reveals an environment of high uncertainty. Considering the average volume over the past ten days was 3,565,306, compared to the three-month average of 2,162,231, these figures suggest fluctuating investor interest relative to historical norms.
Earnings Analysis
In the most recent earnings report dated May 7, 2026, RXO reported earnings per share (EPS) of -$0.09, matching analysts’ expectations and indicating no surprise for investors this quarter. Contrasting previous earnings results, the prior quarter revealed an EPS of -$0.07 against an estimate of -$0.04, presenting a significant negative surprise factor of 75%. While the latest results meet estimates, the trend of negative EPS should raise questions regarding the company’s operational effectiveness and profitability, factors that investors should closely monitor moving forward.
Analyst Consensus View
The overall consensus among analysts appears cautiously optimistic for RXO. Out of 11 total ratings, there are four Buy, five Hold, and two Sell recommendations. The average price target among analysts who cover the stock stands at approximately $20.18, with the high at $26 and the low at $14. This distribution suggests a range of sentiments towards RXO’s near-term performance and long-term potential, yet the recent Buy rating from Stifel’s Chan presents a favorable context for investors looking for upward mobility in their investments.
Stock Grading and Fundamental View
RXO’s Stocks Telegraph Grade (ST Score) currently resides at 46, which indicates a mixed but somewhat concerning view of the company’s overall investment profile. In the context of its financial health and market conditions, this score could suggest that RXO is at a crucial juncture where the ability to innovate and navigate challenges will determine its future standing in the sector.
Conclusion
In summary, RXO, Inc. presents a complex investment landscape characterized by recent positive analyst sentiment and significant price movement potential. Long-term investors who can endure market volatility may find RXO appealing, especially given the analyst’s outlook for substantial upside. However, this stock is not without its risks, given the historical loss trajectory and current financial performance indicators. Investors should proceed with caution, keeping a close watch on the company’s ability to improve operational efficiency and return to profitability in the coming quarters. For those with a higher risk tolerance and a focus on potential rebounds, RXO remains a stock worth watching.